Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445523 · ClinicalTrials.gov registry record · Phase 2
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00445523 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 28 participants.
The verdict
NCT00445523, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.
Interventions
- DRUG Interferon-alpha
- BIOLOGICAL TroVax® (Immunological Vaccine Therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445523
The ClinicalTrials.gov registry entry for NCT00445523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Interferon-alpha is the first listed.
NCT00445523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00445523 about?
NCT00445523 is a clinical study titled "Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer". Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.
What is the current status of trial NCT00445523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2006-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00445523?
The interventions under investigation include: Interferon-alpha (DRUG), TroVax® (Immunological Vaccine Therapy) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00445523?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.